Gland Pharma Limited (NSE:GLAND)
India · Delayed Price · Currency is INR 2,819.30
-0.70 (-0.02%)
Aug 21, 2026, 3:29 PM IST
Gland Pharma Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Gland Pharma stock has a consensus rating of "Buy" and an average price target of ₹2,856. The average 1-year stock price forecast is 1.30% higher than the current stock price, while the lowest is ₹1,940 (-31.19%) and the highest is ₹3,350 (+18.82%).
Price Target: ₹2,856 (+1.30%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Gland Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 2 | 2 | 0 | 0 | 0 | 1 |
| Strong Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Total | 13 | 13 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Upgrades ₹2,080 → ₹3,350 | Buy | Upgrades | ₹2,080 → ₹3,350 | +18.82% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
74.85B
from 64.31B
Increased by 16.39%
Revenue Next Year
85.66B
from 74.85B
Increased by 14.45%
EPS This Year
79.75
from 63.01
Increased by 26.57%
EPS Next Year
96.56
from 79.75
Increased by 21.07%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.